Alevin Therapeutics develops small‑molecule integrin antagonists that selectively block integrin receptors involved in collagen deposition and scar tissue formation. Their platform creates drug‑like candidates suitable for inhaled, oral, or intravenous delivery, targeting high‑unmet‑need fibrotic conditions such as chronic kidney disease and acute kidney injury.
Funding
Funding not disclosed
Founders
Product
Problem
Fibrotic diseases such as chronic kidney disease, acute kidney injury, and cancer-related fibrosis lack effective therapies that can halt or reverse scar tissue formation, leading to progressive organ dysfunction and high mortality.
Solution
Alevin Therapeutics develops precision medicines that selectively antagonize integrin receptors, which are key regulators of collagen deposition and scar tissue buildup. By designing small‑molecule integrin antagonists with drug‑like properties, the company creates candidates suitable for inhaled, oral, or intravenous delivery. These agents aim to modulate the cellular pathways driving fibrosis, offering a targeted approach that minimizes off‑target effects. Preclinical programs focus on generating potent, selective compounds and advancing them through biological and clinical evaluation to address unmet needs in fibrotic conditions.
Target Audience
Primary customers are pharmaceutical partners and clinical research organizations developing treatments for fibrotic diseases, as well as healthcare providers seeking novel anti‑fibrotic therapies.
Features
- Small‑molecule integrin antagonists engineered for high potency and selectivity against specific integrin subtypes involved in fibrosis
- Optimized physicochemical profiles enabling multiple administration routes (inhaled, oral, intravenous)
- Integrated platform combining chemical synthesis, structural biology, and pharmacology to accelerate candidate discovery
- Preclinical pipeline targeting high‑unmet‑need fibrotic indications such as chronic kidney disease and acute kidney injury
- Emphasis on safety and efficacy through rigorous biological and early clinical evaluation